Table 1.

Main characteristics of eligible trials

Indication	Study, reference	Treatment duration, daily dose	Maximum daily paracetamol dose allowed%	Primary efficacy outcome measure +	Number of patients#
					EPs 7630	Placebo
Acute tonsillopharyngitis	A Timen et al., 2015 [60]	6 days: Day 1–2: 20 drops hourly while awake, Day 3–6: 3 × 20 drops	Up to 3 × 500 mg on days 0 to day 4	Response: TSS (7 symptoms) ≤ 4 points at day 4	40	38
	B Berezhnoi et al., 2016 [55]	6 days: 3 × 20 drops		TSS (5 symptoms): difference baseline – day 4	60	64
	C Bereznoy et al., 2003 [56]	6 days: 3 × 20 drops		TSS (5 symptoms): difference baseline – day 4	73	70
Acute bronchitis	D Kamin et al., 2010a [58]	7 days: Age ≤ 6: 3 × 10 drops Age 7–10: 3 × 20 drops	Age ≤ 6: 3 × 250 mg Age 7–10: 3 × 500 mg	BSS: difference baseline – day 7	25§	24§
	E Kamin et al., 2010b [59]	7 days: 3 × 20 mg (tablets)	3 × 500 mg	BSS: difference baseline – day 7	32§&	31§
	F Kamin et al., 2012 [57]	7 days: Age ≤ 6: 3 × 10 drops, Age 7–10: 3 × 20 drops	Age ≤ 6: 3 × 250 mg Age 7–10: 3 × 500 mg	BSS: difference baseline – day 7	35§	31§

^% Only allowed on days with fever ≥38.5 °C

⁺ TSS Tonsillopharyngitis Symptom Score (total score), BSS Bronchitis Symptom Score (total score)

^# Primary efficacy analysis data set (full analysis set)

^§ Only children 6–10 years of age

^& Only children randomised to 3 × 20 mg/day